Krystal Biotech, Inc. Common Stock Earnings Dividend

Krystal Biotech, Inc. Common Stock’s revenue jumped 24.14% since last year same period to $119.22Mn in the Q2 2026. On a quarterly growth basis, Krystal Biotech, Inc. Common Stock has generated 2.46% jump in its revenue since last 3-months.

Krystal Biotech, Inc. Common Stock’s net profit jumped 42.87% since last year same period to $54.77Mn in the Q2 2026. On a quarterly growth basis, Krystal Biotech, Inc. Common Stock has generated -2.08% fall in its net profits since last 3-months.

Krystal Biotech, Inc. Common Stock’s net profit margin jumped 15.1% since last year same period to 45.94% in the Q2 2026. On a quarterly growth basis, Krystal Biotech, Inc. Common Stock has generated -4.43% fall in its net profit margins since last 3-months.

Krystal Biotech, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.7 - a 19.72% jump from last quarter’s estimates.

Krystal Biotech, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.7.

Krystal Biotech, Inc. Common Stock’s earning per share (EPS) jumped 38.76% since last year same period to 1.79 in the Q2 2026. This indicates that the Krystal Biotech, Inc. Common Stock has generated 38.76% annual rate of jump in its earning per share (EPS) in the last 4 quarters.